A Román1, A Perez-Rozos2,3, A Otero2, C Jodar2, I García-Ríos2, Y Lupiañez-Perez2, J Antonio Medina2, J Gomez-Millan4. 1. Department of Radiation Oncology, Hospital Universitario Virgen de La Victoria, Campus Teatinos s/n 29010, Málaga, Spain. aliciajobac@gmail.com. 2. Department of Radiation Oncology, Hospital Universitario Virgen de La Victoria, Campus Teatinos s/n 29010, Málaga, Spain. 3. Departamento de Radiología y Medicina Física, Universidad de Málaga, Málaga, Spain. 4. Department of Radiation Oncology, Hospital Universitario Virgen de La Victoria, Campus Teatinos s/n 29010, Málaga, Spain. jaimegomezmillan@gmail.com.
Abstract
BACKGROUND: Evaluate the safety, toxicity and efficacy of an institutional-simplified SBRT protocol with two short SBRT regimens (three or five fractions) for the treatment of lung cancer and oligometastases, according to the volume and localization of tumours. METHODS: Patients with stage I (T1 or T2) non-small cell lung cancer or lung oligometastases were treated from August 2011 to October 2015. Patients were required to be considered medically inoperable and were discussed in a multidisciplinary team. RESULTS: 100 patients were analysed, 59 had a peripheral location (P), and 41 a central location (C).All patients finished their SBRT course without interruptions related to acute toxicity. The most frequent acute toxicity was grade 1 asthenia, only one patient developed grade 3 toxicity (pneumonitis) and there were no grade 4 or 5 acute toxicities. Three asymptomatic radiation-induced rib fractures were identified, the 1 and 2-year rib fracture-free survival were 97% and 94%, respectively. Two-year progression-free survival and 2-year overall survival of all patients were 52% and 70%, respectively, with a median PFS and OS of 26 and 43 months. Survival free of local progression (SFLP) at 2 years was 89%. A higher PFS in primary lung cancer compared with metastatic tumours was observed, with a median of 35 months with 19 months (p = 0.01). However, no statistical difference was observed in terms of OS between both diseases. CONCLUSIONS: SBRT in lung cancer with three sessions for peripheral tumours and five sessions for central tumours may be safely delivered, with low morbidity.
BACKGROUND: Evaluate the safety, toxicity and efficacy of an institutional-simplified SBRT protocol with two short SBRT regimens (three or five fractions) for the treatment of lung cancer and oligometastases, according to the volume and localization of tumours. METHODS:Patients with stage I (T1 or T2) non-small cell lung cancer or lung oligometastases were treated from August 2011 to October 2015. Patients were required to be considered medically inoperable and were discussed in a multidisciplinary team. RESULTS: 100 patients were analysed, 59 had a peripheral location (P), and 41 a central location (C).All patients finished their SBRT course without interruptions related to acute toxicity. The most frequent acute toxicity was grade 1 asthenia, only one patient developed grade 3 toxicity (pneumonitis) and there were no grade 4 or 5 acute toxicities. Three asymptomatic radiation-induced rib fractures were identified, the 1 and 2-year rib fracture-free survival were 97% and 94%, respectively. Two-year progression-free survival and 2-year overall survival of all patients were 52% and 70%, respectively, with a median PFS and OS of 26 and 43 months. Survival free of local progression (SFLP) at 2 years was 89%. A higher PFS in primary lung cancer compared with metastatic tumours was observed, with a median of 35 months with 19 months (p = 0.01). However, no statistical difference was observed in terms of OS between both diseases. CONCLUSIONS: SBRT in lung cancer with three sessions for peripheral tumours and five sessions for central tumours may be safely delivered, with low morbidity.
Authors: Achilles J Fakiris; Ronald C McGarry; Constantin T Yiannoutsos; Lech Papiez; Mark Williams; Mark A Henderson; Robert Timmerman Journal: Int J Radiat Oncol Biol Phys Date: 2009-02-27 Impact factor: 7.038
Authors: Carlos M Mery; Anastasia N Pappas; Raphael Bueno; Yolonda L Colson; Philip Linden; David J Sugarbaker; Michael T Jaklitsch Journal: Chest Date: 2005-07 Impact factor: 9.410
Authors: Simon S Lo; Achilles J Fakiris; Eric L Chang; Nina A Mayr; Jian Z Wang; Lech Papiez; Bin S Teh; Ronald C McGarry; Higinia R Cardenes; Robert D Timmerman Journal: Nat Rev Clin Oncol Date: 2009-12-08 Impact factor: 66.675
Authors: Catherine Okoukoni; Sarah K Lynch; Emory R McTyre; David M Randolph; Ashley A Weaver; A William Blackstock; Brian E Lally; Michael T Munley; Jeffrey S Willey Journal: Radiother Oncol Date: 2016-04-09 Impact factor: 6.280
Authors: Thibaud P Coroller; Raymond H Mak; John H Lewis; Elizabeth H Baldini; Aileen B Chen; Yolonda L Colson; Fred L Hacker; Gretchen Hermann; David Kozono; Edward Mannarino; Christina Molodowitch; Jon O Wee; David J Sher; Joseph H Killoran Journal: PLoS One Date: 2014-04-11 Impact factor: 3.240
Authors: Subba R Digumarthy; Dexter P Mendoza; Jessica J Lin; Marguerite Rooney; Andrew Do; Emily Chin; Beow Y Yeap; Alice T Shaw; Justin F Gainor Journal: Cancers (Basel) Date: 2020-03-15 Impact factor: 6.639